50% of patients (3/6) with baseline HBsAg <1000 IU/mL achieved a functional cure (defined as sustained HBsAg loss and HBV DNA less than the lower limit of quantification (LLOQ) 24 weeks off all ...
On Friday, Vir Biotechnology, Inc. (NASDAQ:VIR) announced end-of-treatment data from Part B of the MARCH Phase 2 study ...
Nammi Therapeutics has commenced the first in-human Phase I trial of QXL138AM by dosing the first subject for treating ...
Patient dosing has begun in a phase 1 trial evaluating QXL138AM, a masked immunocytokine targeting CD138, in advanced solid ...
Arbutus Biopharma (ABUS) announced new data from its IM-PROVE I Phase 2a clinical trial showing that six doses of imdusiran, the ...
Cite this: The Antifibrotic Effect of Interferon Alfa in the Treatment of Chronic Hepatitis C: An Unanticipated but Important End Point - Medscape - Jun 13, 2000. Dr. Dufour is Assistant Professor ...
Among patients with polycythemia vera, the treatment pairing of Jakafi and Pegasys shows benefits with acceptable toxicity, ...
producing IFN-α(Interferon-alpha) and IL-33 (Interleukin-33). Depletion of pDCs or inhibition of IFN-α or IL-33-mediated ...
Nammi Therapeutics begins patient dosing in phase 1 study of QXL138AM for advanced solid tumours and multiple myeloma: Los Angeles Monday, November 11, 2024, 13:00 Hrs [IST] Nammi ...
In conclusion, this intriguing report builds on the work of many other groups by further unraveling MECP2 function in the ...
In view of the single agent activities of IFN-alpha and IL-2, and preclinical data suggesting that these 2 cytokines have synergistic antitumor activity, [30] a series of clinical trials combining ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback